Neoplasm Metastasis clinical trials at UCSF
3 in progress, 2 open to eligible people
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
open to eligible people ages 12 years and up
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
San Francisco, California and other locations
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
open to eligible people ages 18 years and up
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
San Francisco, California and other locations
9-ING-41 in Patients With Advanced Cancers
Sorry, not currently recruiting here
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
San Francisco, California and other locations
Our lead scientists for Neoplasm Metastasis research studies include Brian Schulte, MD Adil Daud.
Last updated: